Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome.
Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome.
复制标题
DOI:
10.1093/sleep/zsaa220
复制
发表时间:
2021-04-09
期刊:
影响因子:
5.6
通讯作者:
Page GP
中科院分区:
文献类型:
--
作者:
Earley EJ;Didriksen M;Spencer BR;Kiss JE;Erikstrup C;Pedersen OB;Sørensen E;Burgdorf KS;Kleinman SH;Mast AE;Busch MP;Ullum H;Page GP
Restless legs syndrome (RLS) is a common sensorimotor disorder, which can disrupt sleep and is thought to be caused in part by low cellular iron stores. Proton pump inhibitors (PPI) and histamine H2-receptor antagonists (H2A) are among the most commonly used drugs worldwide and show evidence of causing iron deficiency. We conducted a case/non-case observational study of blood donors in the United States (N = 13,403; REDS-III) and Denmark (N = 50,323; Danish Blood Donor Study, DBDS), both of which had complete blood count measures and a completed RLS assessment via the Cambridge–Hopkins RLS questionnaire. After adjusting for age, sex, race, BMI, blood donation frequency, smoking, hormone use, and iron supplement use, PPI/H2A use was associated with RLS (odds ratio [OR] = 1.41; 95% confidence interval [CI], 1.13–1.76; p = 0.002) in REDS-III for both PPI (OR = 1.43; CI, 1.03–1.95; p = 0.03) and H2A (OR = 1.56; CI, 1.10–2.16; p = 0.01). DBDS exhibited a similar association with PPIs/H2As (OR = 1.29; CI, 1.20–1.40; p < 0.001), and for PPIs alone (OR = 1.27; CI, 1.17–1.38; p < 0.001), but not H2As alone (OR = 1.18; CI, 0.92–1.53; p = 0.2). We found no evidence of blood iron stores mediating this association. The association of PPI, and possibly H2A, consumption with RLS independent of blood iron status and other factors which contribute to RLS risk suggest the need to re-evaluate use of PPI/H2A in populations at particular risk for RLS.
登录
查看更多内容
DOI:
10.1016/s0140-6736(17)31928-1
发表时间:
2017-11-25
期刊:
Lancet (London, England)
影响因子:
--
作者:
Di Angelantonio E;Thompson SG;Kaptoge S;Moore C;Walker M;Armitage J;Ouwehand WH;Roberts DJ;Danesh J;INTERVAL Trial Group
通讯作者:
INTERVAL Trial Group
影响因子:
--
作者:
Allen, RP;Walters, AS;Ferini-Strambi, L
通讯作者:
Ferini-Strambi, L
影响因子:
--
作者:
Dignass A;Farrag K;Stein J
通讯作者:
Stein J
影响因子:
2.8
作者:
Cotter, Paul E;O'Keeffe, Shaun T
通讯作者:
O'Keeffe, Shaun T
影响因子:
4.8
作者:
Allen, Richard P.;Adler, Charles H.;Earley, Christopher J.
通讯作者:
Earley, Christopher J.